Claims
- 1. An oxazoline (trifluoroethyl) amine of the formula ##STR32## wherein R.sub.1 and R.sub.2, the same or different, are hydrogen, lower alkoxy of 1 to 6 carbon atoms, inclusive, lower alkyl of 1 to 6 carbon atoms, inclusive, halogen, or trifluoromethyl,
- R.sub.3 is hydrogen, methyl, or ethyl,
- R.sub.4 is hydrogen, methyl, ethyl, or cyclopropyl,
- R is hydrogen or lower alkyl of 1 to 6 carbon atoms, inclusive,
- B is --CH.dbd.CH--, and
- n is zero, 1 or 2.
- 2. A salt of a compound of formula I with a therapeutically-compatible mineral or organic acid.
- 3. An optically-active levorotatory isomer of a compound of formula I or an acid addition salt thereof.
- 4. The oxazolines of claim 1 in racemic form.
- 5. dl .alpha.-trifluoromethyl 2-(4-chlorobenzylamino) oxazoline according to claim 1.
- 6. dl .alpha.-pentafluoroethyl 2-benzylamino oxazoline according to claim 1.
- 7. dl .alpha.-trifluoromethyl 2-(4-methoxy benzylamino) oxazoline according to claim 1.
- 8. dl .alpha.-trifluoromethyl 2-benzylamino oxazoline according to claim 1.
- 9. dl .alpha.-trifluoromethyl 2-(2-methylbenzylamino) oxazoline according to claim 1.
- 10. .alpha.-trifluoromethyl 2-benzylamino oxazoline (dextrorotatory isomer) according to claim 1.
- 11. dl .alpha.-trifluoromethyl 2-(3-trifluoromethyl benzylamino) oxazoline according to claim 1.
- 12. .alpha.-trifluoromethyl 2-benzylamino oxazoline (levorotatory isomer) according to claim 1.
- 13. dl .alpha.-trifluoromethyl 2-(N-methylbenzylamino) oxazoline according to claim 1.
- 14. The pharmaceutical compositions containing as active ingredient at least one compound of claim 1 or an acid addition salt thereof, in admixture or conjunction with an inert non-toxic pharmaceutically-acceptable carrier or diluent intendedfor oral, parental, subligual, percutaneous or rectal ways of administration.
- 15. The pharmaceutical compositions of claim 14 wherein the amount of active ingredient ranges from 0.1 to 2 mg per unit dosage.
- 16. A method for treating hypertension in mammals which consists in administering to said patients suffering from this ailment an amount of a compound of claim 1, which is effective for alleviating said condition.
- 17. The method of claim 16 in which the amount of active ingredient ranges from 0.0016 mg/Kg to 0.083 mg/Kg per day.
Priority Claims (1)
Number |
Date |
Country |
Kind |
76 15601 |
May 1976 |
FRX |
|
Parent Case Info
This application is a divisional of application Ser. No. 31,386, filed Apr. 19, 1979, now U.S. Pat. No. 4,267,345, issued May 12, 1981, which in turn is a continuation-in-part of application Ser. No. 798,830 filed May 20, 1977, now abandoned.
US Referenced Citations (2)
Divisions (1)
|
Number |
Date |
Country |
Parent |
31386 |
Apr 1979 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
798830 |
May 1977 |
|